Absci Corporation

NASDAQ:ABSI

Biotechnology

Healthcare
$8.18 +1.04%

+$0.08 today

Market cap
$1.41B
Beta
2.46
P/E (TTM)
-9.4
EPS (TTM)
-$0.77
52W Low $2.24High $8.17

Volume 5.66M

Average 5.10M

ABSI Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Absci CorporationNASDAQ: ABSI

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures grows, but more slowly than its trailing trend

Q1 FY2026 capital expenditures of $30K (cash outflow) rose 20.0% year over year, behind the +159.2% change in trailing-twelve-month capital expenditures. Over 3 fiscal years it compounded at -59.1% a year.

Context

  • Capital expenditures amounted to 39.5% of revenue in FY2025, up 30.6 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +20.0% toward the trailing-twelve-month pace of +159.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$30K-129.1% QoQ
Last fiscal yearDec 2025
-$1.11M+174.0% YoY
LTMMar 2026
-$1.11M+159.2% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.0%——
1 year+174.0%——
3-year CAGR-59.1%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(1.11M) USD
Year-over-year change
-174.0%

Capital Expenditures vs competitors

How ABSI compares with its peers on the latest reported figures

  • ABSI's LTM Mar 2026 capital expenditures of $1.11M is the smallest of the 3 companies compared; the peer median is $10.47M.
  • Its year-over-year change of +159.2% is the highest of 3, against a peer median of -31.1%.
  • Capital expenditures amounts to 60.6% of revenue for ABSI, versus a peer median of 18.3%.
ABSI Competitors Peer median
Capital Expenditures for ABSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABCLAbCellera Biologics Inc.LTM Sep 2026$17.42M -64.1%-16.2%25.7%
GENBGenerate Biomedicines, Inc.FY2025$3.51M +1.9%—11.0%
ABSIAbsci CorporationLTM Mar 2026$1.11M +159.2%-59.1%60.6%
Peer median (excluding ABSI) $10.47M-31.1%-16.2%18.3%

Competitors are the stored peer set for ABSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(100.96M)(104.9M)(110.57M)(103.11M)(115.18M)
Depreciation & Amortization6.65M13.1M14M13.39M11.74M
Deferred Income Tax(8.9M)(505K)(52K)00
Stock-Based Compensation10.61M12.54M11.42M19.45M18.32M
Change in Working Capital(3.15M)(1.54M)1.52M(368K)423K
Accounts Receivables230K(148K)(666K)2.24M0
Inventory00000
Accounts Payables1.57M(533K)(786K)2.03M1.09M
Other Working Capital(4.95M)(859K)2.97M(4.63M)(671K)
Other Non-Cash Items35.15M(30K)19.05M(1.77M)(8.23M)
Operating Cash Flow(60.6M)(81.34M)(64.64M)(72.4M)(92.93M)
Capital Expenditures(38.05M)(16.18M)(860K)(404K)(1.11M)
Acquisitions (Net)(28.13M)(8M)001.31M
Purchases of Investments(1.2M)(108.59M)(147.35M)(186.11M)(119.87M)
Sales of Investments05M229.9M144M69.5M
Other Investing Activities0783K254K939K0
Investing Cash Flow(67.38M)(126.98M)81.94M(41.58M)(50.16M)
Debt Repayment120.85M4.58M(5.35M)(4.03M)(3.2M)
Common Stock Issued210.4M656K862K86.56M109.15M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow336.19M5.24M(4.48M)82.53M105.95M
Effect of Forex Changes00000
Net Change in Cash208.22M(203.08M)12.83M(31.45M)(37.14M)
Free Cash Flow(98.65M)(97.51M)(65.5M)(72.81M)(94.03M)

Absci Corporation

NASDAQ:ABSI

Intrinsic Alpha fair value

Locked

Current Price

$8.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.